Log in to search using one of your social media accounts:

 

How to Approach a Hodgkin Lymphoma Patient With Relapse After Autologous SCT: Allogeneic SCT

Hodgkin lymphoma (HL) is a highly curable B-cell lymphoma, and ∼90% of patients who present with early-stage (stage I-II) disease and 70% of patients who present with late-stage disease will be cured with standard frontline treatment. For patients with relapsed or refractory (r/r) disease after initial therapy, the standard of care is salvage chemotherapy, fo llowed by autologous transplantation (autoSCT). Although this approach will cure a significant proportion of patients, upto 50% of patients will experience disease progression after autoSCT, and this population has historically had a very poor prognosis.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Source Type: research

Related Links:

Publication date: Available online 31 March 2018 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Steven M. Bair, Anthony Mato, Jakub Svoboda Classical Hodgkin lymphoma (cHL) is one of the most common lymphomas in the Western world. Though the majority of patients are cured with standard frontline therapy, up to 20% of patients will have relapsed or refractory disease. Though the conventional approach to treatment has consisted of chemotherapy, radiation, and for those that relapse, autologous or allogeneic transplantation, newer approaches have become available in recent years, including immunoconjugates and chec...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion Our results are encouraging and justify evaluation of TECAM versus BEAM (carmustine, etoposide, cytarabine, melphalan) in a prospective multicenter study in a large homogenous patient population. Micro-Abstract High-dose chemotherapy and autologous stem cell transplantation (ASCT) is the current standard of care for relapsed lymphoma. We retrospectively analyzed the data from 212 lymphoma patients who had undergone ASCT with the TECAM conditioning regimen. The 3-year overall survival, progression-free survival, and death resulting from treatment were comparable to those reported with other conditioning regimens....
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
In January, 2018, Academic Press published my bookPrecision Medicine and the Reinvention of Human Disease. This book has an excellent " look inside " at itsGoogle book site, which includes the Table of Contents. In addition, I thought it might be helpful to see the topics listed in the Book's index. Note that page numbers followed by f indicate figures, t indicate tables, and ge indicate glossary terms.AAbandonware, 270, 310geAb initio, 34, 48ge, 108geABL (abelson leukemia) gene, 28, 58ge, 95 –97Absidia corymbifera, 218Acanthameoba, 213Acanthosis nigricans, 144geAchondroplasia, 74, 143ge, 354geAcne, 54ge, 1...
Source: Specified Life - Category: Information Technology Tags: index jules berman jules j berman precision medicine Source Type: blogs
Conclusion Our results suggest that achievement of a CR is imperative in patients with advanced ENKL, and is desirable for any patient for whom auto-SCT is utilized. SMILE-based chemotherapy appeared effective in attaining a CR, and was also an effective salvage regimen. For patients attaining a first CR, auto-SCT should be strongly considered, but should definitely be utilized in patients attaining CR2. For patients with refractory disease, allo-SCT can be considered in a selected group of patients. Micro-Abstract We present a cohort of primarily non-Asian patients with advanced stage and relapsed/refractory ENKL. Our res...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion CNS-directed high-dose chemotherapy and ASCT provides durable remission for patients with synchronous aggressive lymphoma and should be strongly considered as consolidative therapy for eligible patients with systemic NHL with CNS involvement in first complete remission. Micro-Abstract Systemic non-Hodgkin lymphoma with synchronous central nervous system involvement traditionally carries a poor prognosis. We found encouraging results with the use of high-dose chemotherapy and autologous stem cell transplantation as consolidation for patients in first complete remission. Central nervous system-directed conditionin...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 15 November 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Matthew Mei, Robert Chen Hodgkin lymphoma (HL) is a highly curable B-cell lymphoma, and ∼90% of patients who present with early-stage (stage I-II) disease and 70% of patients who present with late-stage disease will be cured with standard frontline treatment. For patients with relapsed or refractory (r/r) disease after initial therapy, the standard of care is salvage chemotherapy, followed by autologous transplantation (autoSCT). Although this approach will cure a significant proportion of patients, upto 5...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Hodgkin lymphoma (HL) is a highly curable B-cell lymphoma, and approximately 90% of patients who present with early stage (I-II) disease (1) and 70% of patients who present with late-stage disease will be cured with standard frontline treatment(2). For patients with relapsed or refractory (r/r) disease after initial therapy, the standard of care is salvage chemotherapy followed by autologous transplant (autoSCT). While this approach will cure a significant proportion of patients, up to 50% of patients will experience disease progression after autoSCT(3), and this population has historically had a very poor prognosis.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Extra-nodal natural killer/T-cell lymphoma (ENKL) is a rare lymphoma representing approximately 5-10% of T-cell non-Hodgkin lymphomas diagnosed in the United States each year.1, 2 ENKL is universally associated with Epstein-Barr virus (EBV) infection, and is more frequent in Asian, Central American and South American populations, where it constitutes 5-15% of all lymphomas.3-5 Patients with advanced stage ENKL (stage III-IV) and relapsed/refractory early stage disease are treated with systemic chemotherapy with or without radiotherapy.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Early stage classical Hodgkin lymphoma (cHL) has a high rate of cure for patients for are interim PET/CT-2 or 3 negative (1, 2) Thus, given this there is an increased focus on treatment de-escalation for patients with a negative interim PET/CT scan including decreasing number of cycles of chemotherapy, adding in biologic therapies, and decreasing radiation ranging from decreasing radiation doses and field sizes to eliminating radiation. However, for patients who have residual disease activity on interim PET/CT (1,  2) the outcomes remain challenging in that often ultimately these patients develop refractory disease th...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Conclusion CNS-directed high-dose chemotherapy and ASCT provides durable remission for patients with synchronous aggressive lymphoma and should be strongly considered as consolidative therapy for eligible patients with systemic NHL with CNS involvement in CR1. Teaser Systemic non-Hodgkin lymphoma with synchronous central nervous system (CNS) involvement traditionally carries a poor prognosis. We found encouraging results with the use of high-dose chemotherapy and autologous stem cell transplantation as consolidation for patients in first complete remission. CNS-directed conditioning with a thiotepa-based regimen might redu...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Chemotherapy | Hematology | Hodgkin's Disease | Leukemia | Lymphoma | Myeloma | Transplants